Evolent Health Inc (NYSE:EVH) CEO Frank J. Williams sold 41,015 shares of the business’s stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $24.02, for a total transaction of $985,180.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Frank J. Williams also recently made the following trade(s):

  • On Wednesday, August 1st, Frank J. Williams sold 9,653 shares of Evolent Health stock. The shares were sold at an average price of $19.97, for a total transaction of $192,770.41.
  • On Monday, July 2nd, Frank J. Williams sold 10,231 shares of Evolent Health stock. The shares were sold at an average price of $21.22, for a total transaction of $217,101.82.
  • On Thursday, June 21st, Frank J. Williams sold 47,314 shares of Evolent Health stock. The shares were sold at an average price of $24.00, for a total transaction of $1,135,536.00.
  • On Friday, June 1st, Frank J. Williams sold 15,000 shares of Evolent Health stock. The shares were sold at an average price of $20.04, for a total transaction of $300,600.00.

EVH traded down $0.25 during trading hours on Friday, hitting $23.75. 34,718 shares of the company’s stock were exchanged, compared to its average volume of 871,715. Evolent Health Inc has a 12-month low of $10.30 and a 12-month high of $24.15. The company has a market cap of $1.71 billion, a P/E ratio of -33.93 and a beta of 1.06. The company has a quick ratio of 2.59, a current ratio of 2.59 and a debt-to-equity ratio of 0.12.

Evolent Health (NYSE:EVH) last announced its earnings results on Tuesday, August 7th. The technology company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.01. Evolent Health had a negative net margin of 9.84% and a negative return on equity of 1.82%. The firm had revenue of $144.51 million for the quarter, compared to the consensus estimate of $141.90 million. research analysts forecast that Evolent Health Inc will post -0.34 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. State of Wisconsin Investment Board increased its stake in Evolent Health by 25.0% during the 1st quarter. State of Wisconsin Investment Board now owns 500,000 shares of the technology company’s stock worth $7,125,000 after buying an additional 100,000 shares during the period. Cortina Asset Management LLC increased its position in shares of Evolent Health by 10.9% in the 1st quarter. Cortina Asset Management LLC now owns 458,662 shares of the technology company’s stock valued at $6,536,000 after purchasing an additional 45,256 shares during the last quarter. Northern Trust Corp increased its position in shares of Evolent Health by 2.1% in the 1st quarter. Northern Trust Corp now owns 834,169 shares of the technology company’s stock valued at $11,886,000 after purchasing an additional 16,912 shares during the last quarter. Chicago Capital LLC purchased a new stake in shares of Evolent Health in the 1st quarter valued at approximately $12,254,000. Finally, Rhumbline Advisers increased its position in shares of Evolent Health by 8.2% in the 1st quarter. Rhumbline Advisers now owns 57,923 shares of the technology company’s stock valued at $825,000 after purchasing an additional 4,370 shares during the last quarter.

A number of equities research analysts have recently issued reports on the stock. MED boosted their price target on shares of Evolent Health from $22.00 to $31.00 and gave the company an “outperform” rating in a research note on Monday, June 18th. Zacks Investment Research raised shares of Evolent Health from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a research note on Tuesday, July 10th. SunTrust Banks boosted their price target on shares of Evolent Health and gave the company a “buy” rating in a research note on Thursday, June 7th. KeyCorp boosted their price target on shares of Evolent Health from $24.00 to $26.00 and gave the company an “overweight” rating in a research note on Thursday, June 7th. Finally, TheStreet raised shares of Evolent Health from a “d+” rating to a “c-” rating in a research note on Monday, June 4th. One investment analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $26.75.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Featured Article: Book Value Of Equity Per Share – BVPS Explained

Insider Buying and Selling by Quarter for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.